A Phase 3 interventional study of Crovalimab and Eculizumab in Paroxysmal Nocturnal Hemoglobinuria, sponsored by Hoffmann-La Roche. Active, not recruiting at 63 sites in 23 countries. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies in Hemoglobinuria, Paroxysmal with a site in Spain — 3 open to participants now, 8 under way, 6 of them phase 3. Hemoglobinuria, Paroxysmal · Spain.
Among the 24 studies in Hemoglobinuria, Paroxysmal with a site in Spain, this one is the 2nd largest by enrollment of the 23 interventional ones that give a count, is one of 3 that started in 2020, is one of 17 in phase 3, and was the 11th registered.
191 studies on the registry are indexed under Hemoglobinuria, Paroxysmal; 49 are open to participants now.
Browse Hemoglobinuria, Paroxysmal studies →3 of the 24 studies in Hemoglobinuria, Paroxysmal with a site in Spain are open now. Recruiting first, the newest first:
Regeneron Pharmaceuticals · Sites in Spain, Brazil, Canada and 4 more countries
Ages 18+
Regeneron Pharmaceuticals · Sites in Spain, Brazil, Canada and 18 more countries
Ages 18+
Apellis Pharmaceuticals, Inc. · Sites in Spain, United States, Czechia and 6 more countries
Ages 12–17
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 30 Hemoglobinuria, Paroxysmal studies recruiting now, 14 (47%) set no upper age limit and 12 (40%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.
This study: 2 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 6 · Phase 3 17
First in 2004; this study’s year is marked. 3 started in 2020.
This study's enrollment of 210 is above the median of 33 across 150 interventional studies indexed under Hemoglobinuria, Paroxysmal.
Median enrollment 85 across the 23 interventional studies, 165 across the 1 observational. Of the 16 that completed or were terminated, 14 (88%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 24 have an industry lead sponsor. The 9 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
Hoffmann-La Roche has 4 studies filed under Hemoglobinuria, Paroxysmal — fewer than ten, so there is no comparison to draw.
2 of the studies in Hemoglobinuria, Paroxysmal with a site in Spain that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04432584Phase 3Hoffmann-La RocheA Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors | 2027-04-18 |
| NCT04747613Phase 3Novartis PharmaceuticalsLong-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal Hemoglobinuria | 2027-10-18 |
Add all 2 to your calendar (.ics) → With an account.
Among the 24 studies in Hemoglobinuria, Paroxysmal with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A study designed to evaluate the non-inferiority of crovalimab compared with eculizumab in participants with PNH who have not been previously treated with complement inhibitor therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Crovalimab will be administered at an initial loading dose of 1000 milligrams (mg) (for participants with body weight between 40 and 100 kilograms \[kg\]) or 1500 mg (for participants with body weight ≥ 100 kg), as intravenous (IV) injection on Day 1 of Week 1 followed by four weekly subcutaneous (SC) injections of 340 mg starting on Day 2 of Week 1 and then once weekly (QW) at Weeks 2,3 and 4. Thereafter crovalimab will be administered, as SC injection, at a maintenance dose of 680 mg (for participants with body weight between 40 and 100 kg) or 1020 mg (for participants with body weight ≥ 100 kg) once every 4 weeks (Q4W) from Week 5 for a total of 24 weeks of study treatment. Participants may continue to receive crovalimab after 24 weeks of treatment up to maximum of 5 years.
Drug: Crovalimab
Participants will receive loading dose of eculizumab 600 mg on Days 1, 8, 15, and 22, followed by maintenance dose of 900 mg on Day 29 and every 2 weeks (Q2W) thereafter until 24 weeks. Participants may switch to receive crovalimab after 24 weeks of eculizumab treatment.
Drug: Crovalimab · Drug: Eculizumab
Participants with a body weight ≥ 5 to \<12 kg will receive a loading series of crovalimab doses comprised of an IV dose on Day 1 of Week 1, followed by crovalimab SC dose on Day 2 Week 1. Maintenance doses will begin at Week 3 and will be administered Q2W, thereafter. Participants with a body weight ≥ 12 to \< 20 kg and ≥ 20 kg will receive a loading series of crovalimab doses comprised of an IV dose on Day 1 of Week 1, followed by weekly crovalimab SC doses for 4 weeks at Week 1 (Day 2) and then at Weeks 2, 3, and 4. Maintenance doses will begin at Week 5 and will be administered Q2W thereafter, for participants with a body weight ≥ 12 to \< 20 kg and Q4W thereafter, for participants with a body weight \> 20 kg. After 24 weeks of crovalimab treatment, participants who derive benefit from the drug may continue to receive crovalimab.
Drug: Crovalimab
Dosing depends on body weight. Participants will be dosed as follows: * 5 kg to \< 12 kg: 100 mg IV on Week 1 Day 1 (W1D1); 85 mg SC on Week 1 Day 2 (W1D2) and Q2W from Week 3 until end of study * 12 kg to \< 20 kg: 200 mg IV on W1D1; 85 mg SC on W1D2, Weeks 2, 3 and 4; 170 mg SC, Q2W from Week 5 until end of study * 20 kg to \< 30 kg: 300 mg IV on W1D1; 85 mg SC on W1D2, Weeks 2, 3 and 4; 340 mg SC, Q4W from Week 5 until end of study * 30 kg to \< 40 kg: 400 mg IV on W1D1; 170 mg SC on W1D2, Weeks 2, 3 and 4; 510 mg SC, Q4W from Week 5 until end of study * 40 kg to \< 100 kg: 1000 mg IV on W1D1; 340 mg SC W1D2, Weeks 2, 3 and 4; 680 mg SC, Q4W from Week 5 until end of study * 100 kg: 1500 mg IV on W1D1; 340 mg SC W1D2, Weeks 2, 3 and 4; 1020 mg SC, Q4W from Week 5 until end of study.
Eculizumab will be administered as specified in the respective arm.
Percentage of Participants With Transfusion Avoidance (TA)
TA is defined as participants who are packed red blood cell (pRBC) transfusion-free and do not require transfusion per protocol-specified guidelines. 95% Confidence Interval (CI) for percentage of participants with TA was calculated using the Wilson's method with continuity correction. Participants who withdrew before Week 25 were deemed to have had a transfusion. Percentages are rounded off to the nearest single decimal.
Time frame: Baseline to Week 25
Percentage of Participants With Hemolysis Control Measured by LDH
A Generalized Estimating Equation (GEE) was used to estimate the population-average percentage of the participants with hemolysis control (measured by LDH ≤1.5 x upper limit of normal (ULN)) from Week 5 to Week 25 taking account of the intra-patient and inter-patient correlation between LDH control statuses across visits. Percentages are rounded off to the nearest single decimal.
Time frame: Week 5 to Week 25
Percentage of Participants With Breakthrough Hemolysis (BTH)
BTH was defined as at least one new or worsening symptom or sign of intravascular hemolysis (fatigue, hemoglobinuria, abdominal pain, shortness of breath \[dyspnea\], anemia \[hemoglobin \< 10 grams per deciliter (g/dL)\], major adverse vascular event \[MAVE, including thrombosis\], dysphagia, or erectile dysfunction) in the presence of elevated LDH ≥2xULN after a prior LDH reduction to ≤1.5xULN from the start of study treatment. 95% CI for percentage of participants with BTH was calculated using the Wilson's method with continuity correction. Participants who withdrew before Week 25 were deemed to have experienced a BTH event. Percentages are rounded off to the nearest single decimal.
Time frame: Baseline to Week 25
Percentage of Participants With Stabilization of Hemoglobin
Stabilized hemoglobin is defined as avoidance of a \>= 2 g/dL decrease in hemoglobin level from baseline, in the absence of transfusion. 95% CI for percentage of participants with stabilized hemoglobin was calculated using the Wilson's method with continuity correction. Participants who withdrew before Week 25 were deemed to not have had hemoglobin stabilization. Percentages are rounded off to the nearest single decimal.
Time frame: Baseline to Week 25
Change From Baseline in Fatigue Assessed by Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Scale
Fatigue was assessed using FACIT-F scale. FACIT-F is a self-assessment questionnaire with a 7-day recall period and 13 items evaluating fatigue and its impact on daily life activities. Items are scored on a response scale that ranges from 0 ("not at all") to 4 ("very much so"). Relevant items are reverse scored, and all the items are summed to create a total score range from 0 to 52, with 0 being the worst possible score and 52 being the best possible score. A higher score indicates low fatigue severity. A positive mean change indicates improvement. FACIT-F was assessed in adult participants only.
Time frame: Baseline to Week 25
Percentage of Participants With Adverse Events (AEs)
An AE is any untoward medical occurrence in a participant administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. AEs are reported based on the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 5.0.
Time frame: Up to 6 years
Percentage of Participants With Injection-Site Reactions, Infusion-Related Reactions, Hypersensitivity and Infections (Including Meningococcal Meningitis)
An AE is any unfavorable and unintended sign, symptom, or disease temporally associated with the use of an investigational product or other protocol-imposed intervention, regardless of attribution. Injection-site reactions or infusion-related reaction are AEs related to the injection site that occur during or within 24 hours after study drug administration that are judged to be related to the study drug injection.
Time frame: Up to 6 years
Percentage of Participants With AEs Leading to Study Drug Discontinuation
An AE is any untoward medical occurrence in a participant administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. AEs are reported based on the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 5.0.
Time frame: Up to 6 years
Percentage of Participants With Clinical Manifestations of Drug-Target-Drug Complex (DTDC) Formation Amongst Participants Who Switched to Crovalimab Treatment From Eculizumab Treatment
Time frame: Up to 6 years
Serum Concentrations of Crovalimab And Eculizumab Over Time
Time frame: Up to 6 years
Percentage of Participants With Anti-Crovalimab Antibodies
Time frame: Up to 6 years
Change in Pharmacodynamic (PD) Biomarkers Including Complement Activity (CH50) Over Time
Time frame: Up to 6 years
Change Over Time in Free C5 Concentration in Crovalimab-Treated Participants
Time frame: Up to 6 years
Observed Value in Reticulocyte Count (Count/Milliliters [mL])
Time frame: Up to 6 years
Observed Value in Haptoglobin (Milligrams Per Deciliter [mg/dL])
Time frame: Up to 6 years
Change From Baseline in Absolute Reticulocyte Count
Time frame: Baseline, Day 1 Week 1, Week 2, 3, 4, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23 and 25
Change From Baseline in Free Hemoglobin
Time frame: Baseline, Week 2, 3, 4, 5, 9, 13, 17, 21, and 25
Change From Baseline in Haptoglobin
Time frame: Baseline, Week 2, 3, 4, 5, 9, 13, 15, 17, 21, and 25
Participants were enrolled at centres in Argentina, Brazil, China, France, Greece, Germany, Hong Kong, Japan, Lithuania, Malaysia, Mexico, Netherlands, Philippines, Poland, Portugal, Romania Republic of Korea, Singapore, Spain, Sweden, Thailand, Türkiye, Taiwan, Ukraine, and United Kingdom from 08 Oct 2020 to 16 Nov 2022. The study is ongoing.
| Milestone | Arm A: Crovalimab | Arm B: Eculizumab | Arm C: Crovalimab |
|---|---|---|---|
| Started | 135 | 69 | 6 |
| Completed | 129 | 68 | 6 |
| Not completed | 6 | 1 | 0 |
| Withdrew: Physician decision | 2 | 0 | 0 |
| Withdrew: Withdrawal by subject | 2 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 |
| Withdrew: Death | 1 | 1 | 0 |
| Milestone | Arm A: Crovalimab | Arm B: Eculizumab | Arm C: Crovalimab |
|---|---|---|---|
| Started | 129 | 68 | 6 |
| Completed | 0 | 0 | 0 |
| Not completed | 129 | 68 | 6 |
| Withdrew: Treatment (crovalimab) ongoing | 127 | 65 | 6 |
| Withdrew: Withdrawal by subject | 2 | 2 | 0 |
| Withdrew: Adverse event | 0 | 1 | 0 |
TA is defined as participants who are packed red blood cell (pRBC) transfusion-free and do not require transfusion per protocol-specified guidelines. 95% Confidence Interval (CI) for percentage of participants with TA was calculated using the Wilson's method with continuity correction. Participants who withdrew before Week 25 were deemed to have had a transfusion. Percentages are rounded off to the nearest single decimal.
| percentage of participants | Arm A: Crovalimab | Arm B: Eculizumab |
|---|---|---|
| Percentage of Participants With Transfusion Avoidance (TA) | 65.7 (56.91 to 73.52) | 68.1 (55.67 to 78.53) |
A Generalized Estimating Equation (GEE) was used to estimate the population-average percentage of the participants with hemolysis control (measured by LDH ≤1.5 x upper limit of normal (ULN)) from Week 5 to Week 25 taking account of the intra-patient and inter-patient correlation between LDH control statuses across visits. Percentages are rounded off to the nearest single decimal.
| percentage of participants | Arm A: Crovalimab | Arm B: Eculizumab |
|---|---|---|
| Percentage of Participants With Hemolysis Control Measured by LDH | 79.3 (72.86 to 84.48) | 79.0 (69.66 to 85.99) |
BTH was defined as at least one new or worsening symptom or sign of intravascular hemolysis (fatigue, hemoglobinuria, abdominal pain, shortness of breath \[dyspnea\], anemia \[hemoglobin \< 10 grams per deciliter (g/dL)\], major adverse vascular event \[MAVE, including thrombosis\], dysphagia, or erectile dysfunction) in the presence of elevated LDH ≥2xULN after a prior LDH reduction to ≤1.5xULN from the start of study treatment. 95% CI for percentage of participants with BTH was calculated using the Wilson's method with continuity correction. Participants who withdrew before Week 25 were deemed to have experienced a BTH event. Percentages are rounded off to the nearest single decimal.
| percentage of participants | Arm A: Crovalimab | Arm B: Eculizumab |
|---|---|---|
| Percentage of Participants With Breakthrough Hemolysis (BTH) | 10.4 (6.04 to 17.21) | 14.5 (7.54 to 25.50) |
Stabilized hemoglobin is defined as avoidance of a \>= 2 g/dL decrease in hemoglobin level from baseline, in the absence of transfusion. 95% CI for percentage of participants with stabilized hemoglobin was calculated using the Wilson's method with continuity correction. Participants who withdrew before Week 25 were deemed to not have had hemoglobin stabilization. Percentages are rounded off to the nearest single decimal.
| percentage of participants | Arm A: Crovalimab | Arm B: Eculizumab |
|---|---|---|
| Percentage of Participants With Stabilization of Hemoglobin | 63.4 (54.63 to 71.45) | 60.9 (48.35 to 72.17) |
Fatigue was assessed using FACIT-F scale. FACIT-F is a self-assessment questionnaire with a 7-day recall period and 13 items evaluating fatigue and its impact on daily life activities. Items are scored on a response scale that ranges from 0 ("not at all") to 4 ("very much so"). Relevant items are reverse scored, and all the items are summed to create a total score range from 0 to 52, with 0 being the worst possible score and 52 being the best possible score. A higher score indicates low fatigue severity. A positive mean change indicates improvement. FACIT-F was assessed in adult participants only.
| score on scale | Arm A: Crovalimab | Arm B: Eculizumab |
|---|---|---|
| Baseline | 36.02 ± 0.877 | 35.09 ± 1.408 |
| Change at Week 25 | 7.79 ± 0.661 | 5.15 ± 0.880 |
An AE is any untoward medical occurrence in a participant administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. AEs are reported based on the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 5.0.
Results for this outcome have not been posted.
An AE is any unfavorable and unintended sign, symptom, or disease temporally associated with the use of an investigational product or other protocol-imposed intervention, regardless of attribution. Injection-site reactions or infusion-related reaction are AEs related to the injection site that occur during or within 24 hours after study drug administration that are judged to be related to the study drug injection.
Results for this outcome have not been posted.
An AE is any untoward medical occurrence in a participant administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. AEs are reported based on the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 5.0.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
| 10^9 cells/liter (L) | Arm A: Crovalimab | Arm B: Eculizumab |
|---|---|---|
| Baseline | 2865.56 ± 22637.24 | 164.26 ± 114.27 |
| Change at Week 1 Day 1 | -58.50 ± NA | — |
| Change at Week 2 | 542.90 ± 4314.07 | 105.88 ± 601.77 |
| Change at Week 3 | -71.08 ± 533.01 | -15.62 ± 53.79 |
| Change at Week 4 | 8.52 ± 58.01 | -10.56 ± 51.36 |
| Change at Week 5 | -1126.63 ± 9074.19 | 4.85 ± 49.43 |
| Change at Week 7 | -3517.66 ± 26606.21 | 7020.33 ± 38344.72 |
| Change at Week 9 | 12.60 ± 62.05 | 20.65 ± 60.04 |
| Change at Week 11 | 425.66 ± 3343.99 | 26.12 ± 81.80 |
| Change at Week 13 | 24.47 ± 48.92 | 28.61 ± 78.48 |
| Change at Week 15 | -838.52 ± 6735.13 | 37.20 ± 77.52 |
| Change at Week 17 | 1929.82 ± 15576.37 | 33.22 ± 73.34 |
| Change at Week 19 | 62.91 ± 390.39 | 22.16 ± 70.68 |
| Change at Week 21 | 633.95 ± 4919.97 | 15.90 ± 72.72 |
| Change at Week 23 | 698.79 ± 5409.05 | 27.51 ± 85.87 |
| Change at Week 25 | 1396.46 ± 11622.57 | 32.31 ± 97.79 |
| milligram per litre (mg)/L | Arm A: Crovalimab | Arm B: Eculizumab |
|---|---|---|
| Baseline | 474.88 ± 276.49 | 495.69 ± 393.56 |
| Change at Week 2 | -406.39 ± 273.33 | -407.10 ± 339.84 |
| Change at Week 3 | -409.10 ± 286.35 | -393.20 ± 352.22 |
| Change at Week 4 | -413.16 ± 281.40 | -418.00 ± 441.01 |
| Change at Week 5 | -386.62 ± 424.67 | -421.14 ± 402.64 |
| Change at Week 9 | -404.29 ± 298.64 | -405.89 ± 425.73 |
| Change at Week 13 | -409.94 ± 298.14 | -328.56 ± 586.25 |
| Change at Week 17 | -408.15 ± 285.24 | -340.00 ± 503.24 |
| Change at Week 21 | -367.86 ± 341.53 | -387.63 ± 462.10 |
| Change at Week 25 | -431.50 ± 277.83 | -334.96 ± 516.40 |
| gram (g)/L | Arm A: Crovalimab | Arm B: Eculizumab |
|---|---|---|
| Baseline | 0.05 ± 0.00 | 0.05 ± 0.00 |
| Change at Week 2 | 0.05 ± 0.14 | 0.08 ± 0.19 |
| Change at Week 3 | 0.05 ± 0.16 | 0.11 ± 0.28 |
| Change at Week 4 | 0.08 ± 0.21 | 0.12 ± 0.28 |
| Change at Week 5 | 0.06 ± 0.16 | 0.09 ± 0.23 |
| Change at Week 9 | 0.05 ± 0.17 | 0.07 ± 0.23 |
| Change at Week 13 | 0.04 ± 0.17 | 0.06 ± 0.21 |
| Change at Week 17 | 0.05 ± 0.16 | 0.05 ± 0.14 |
| Change at Week 21 | 0.06 ± 0.18 | 0.06 ± 0.22 |
| Change at Week 25 | 0.06 ± 0.17 | 0.05 ± 0.21 |
Collected over From randomization until primary completion date cutoff (up to approximately 25 weeks) Data collected up to 25 weeks are reported here. Adverse event data collection for the Extension Treatment Period is ongoing and will be reported one year after the study completion date.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm A: Crovalimab | 2/135 (1.5%) | 22/135 (16.3%) | 102/135 (75.6%) |
| Arm B: Eculizumab | 1/69 (1.4%) | 14/69 (20.3%) | 55/69 (79.7%) |
| Arm C: Crovalimab | 0/6 (0%) | 0/6 (0%) | 5/6 (83.3%) |
| Event | Arm A: Crovalimab | Arm B: Eculizumab | Arm C: Crovalimab |
|---|---|---|---|
| PneumoniaInfections and infestations | 4/135 | 0/69 | 0/6 |
| Aplastic anaemiaBlood and lymphatic system disorders | 2/135 | 1/69 | 0/6 |
| Upper respiratory tract infectionInfections and infestations | 2/135 | 0/69 | 0/6 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 2/135 | 0/69 | 0/6 |
| AnaemiaBlood and lymphatic system disorders | 0/135 | 1/69 | 0/6 |
| Febrile neutropeniaBlood and lymphatic system disorders | 0/135 | 1/69 | 0/6 |
| ThrombocytopeniaBlood and lymphatic system disorders | 1/135 | 1/69 | 0/6 |
| Cardiac failureCardiac disorders | 0/135 | 1/69 | 0/6 |
| PyrexiaGeneral disorders | 1/135 | 1/69 | 0/6 |
| Cholecystitis chronicHepatobiliary disorders | 0/135 | 1/69 | 0/6 |
| Event | Arm A: Crovalimab | Arm B: Eculizumab | Arm C: Crovalimab |
|---|---|---|---|
| HyperuricaemiaMetabolism and nutrition disorders | 11/135 | 7/69 | 2/6 |
| COVID-19Infections and infestations | 28/135 | 9/69 | 0/6 |
| Aphthous ulcerGastrointestinal disorders | 0/135 | 0/69 | 1/6 |
| FatigueGeneral disorders | 4/135 | 3/69 | 1/6 |
| PyrexiaGeneral disorders | 15/135 | 8/69 | 1/6 |
| Urinary tract infectionInfections and infestations | 5/135 | 5/69 | 1/6 |
| ContusionInjury, poisoning and procedural complications | 2/135 | 1/69 | 1/6 |
| HypocalcaemiaMetabolism and nutrition disorders | 8/135 | 7/69 | 1/6 |
| HypokalaemiaMetabolism and nutrition disorders | 15/135 | 9/69 | 1/6 |
| HypomagnesaemiaMetabolism and nutrition disorders | 3/135 | 1/69 | 1/6 |
All Participant Population includes all participant enrolled to the originally assigned treatment arms (Arms A, B and C).
| Age, Categorical(Participants) | Arm A: Crovalimab | Arm B: Eculizumab | Arm C: Crovalimab | Total |
|---|---|---|---|---|
| <=18 years | 0 | 2 | 6 | 8 |
| Between 18 and 65 years | 122 | 58 | 0 | 180 |
| >=65 years | 13 | 9 | 0 | 22 |
| Sex: Female, Male(Participants) | Arm A: Crovalimab | Arm B: Eculizumab | Arm C: Crovalimab | Total |
|---|---|---|---|---|
| Female | 58 | 34 | 2 | 94 |
| Male | 77 | 35 | 4 | 116 |
| Ethnicity (NIH/OMB)(Participants) | Arm A: Crovalimab | Arm B: Eculizumab | Arm C: Crovalimab | Total |
|---|---|---|---|---|
| Hispanic or Latino | 18 | 6 | 1 | 25 |
| Not Hispanic or Latino | 114 | 61 | 5 | 180 |
| Unknown or Not Reported | 3 | 2 | 0 | 5 |
| Race (NIH/OMB)(Participants) | Arm A: Crovalimab | Arm B: Eculizumab | Arm C: Crovalimab | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 86 | 51 | 5 | 142 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 3 | 1 | 0 | 4 |
| White | 45 | 16 | 0 | 61 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 1 | 1 | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
Ran from Oct 2020 to primary completion in Nov 2022, 25 months.
Results were first posted in Nov 2025, 2 years 11 months after primary completion. A results delay was requested in Nov 2023.
Of 35 industry-sponsored phase 3 interventional studies under Hemoglobinuria, Paroxysmal, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 41. This study's 25 months is close to that.
Counting every sponsor, half of 35 studies reached it within 23 months; a quarter within 15 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Crovalimab